INTHOUGHT TAKES
Read inThought’s expert analyses on hot topics in the pharmaceutical industry.
INTHOUGHT TAKES
Read inThought’s expert analyses on hot topics in the pharmaceutical industry.
Wegovy leadership in obesity remains strong as Lilly doubles down on emerging entry with tirzepatide. While Novo Nordisk continues to have a virtual monopoly on the GLP space for obesity, posting huge growth in uptake and sales of Wegovy, Lilly is close on their heels.